Amedeo Smart

Free Medical Literature Service

 

Amedeo

Stroke
  Free Subscription

Articles published in
Lancet
    September 2026
  1. KLEIN KR, Wysham C, Tuttle KR, Davies MJ, et al
    Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial.
    Lancet. 2026 Sep 30:S0140-6736(26)01865-9. doi: 10.1016/S0140-6736(26)01865.
    >> Share

  2. GOLLEDGE J, Sogaard M, Svensson M, Gupta PC, et al
    Peripheral arterial disease: adverse impacts, disparities in outcomes, and the path ahead.
    Lancet. 2026 Sep 22:S0140-6736(26)00847-0. doi: 10.1016/S0140-6736(26)00847.
    >> Share

  3. BRAZILE TL, Conrad N, Bergman L, Gnanaraj JP, et al
    Cardiovascular disease in pregnancy: physiology, global burden, risk stratification, and opportunities in care.
    Lancet. 2026;408:935-951.
    >> Share

    August 2026
  4. WACHTER R, Haag P, Uhe T, Bacak M, et al
    Catheter ablation for symptomatic atrial fibrillation (PVI-SHAM-AF): a randomised, double-blind, sham-controlled, multicentre trial.
    Lancet. 2026 Aug 30:S0140-6736(26)01558-8. doi: 10.1016/S0140-6736(26)01558.
    >> Share

  5. SILVAIN J, Choi KH, Monguillon V, Kang D, et al
    Discontinuation of beta-blockers in stable patients with previous myocardial infarction, preserved left ventricular ejection fraction, and no heart failure: a pooled analysis of individual patient data.
    Lancet. 2026 Aug 30:S0140-6736(26)01426-1. doi: 10.1016/S0140-6736(26)01426.
    >> Share

  6. BANERJEE G, Edgren G, Zhao J, Ferguson NM, et al
    Risk of transmission of amyloid beta pathology via transfused blood products.
    Lancet. 2026;408:753-760.
    >> Share

    July 2026
  7. RUEL M, Nambala S, Guo MH, Verevkin A, et al
    Multivessel coronary artery bypass grafting via small thoracotomy versus sternotomy (MIST): an investigator-initiated, international, open-label, randomised controlled trial.
    Lancet. 2026 Jul 31:S0140-6736(26)01288-2. doi: 10.1016/S0140-6736(26)01288.
    >> Share

  8. MINNEN OV, Lansink-Hartgring AO, van Amstel RBE, van den Bogaard B, et al
    Standard-dose unfractionated heparin versus low-dose unfractionated heparin and low-molecular-weight heparin in extracorporeal life support (RATE): an open-label, randomised, non-inferiority trial.
    Lancet. 2026;408:357-366.
    >> Share

  9. SOTOMI Y, Kozuma K, Higuchi Y, Nakazawa G, et al
    1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial.
    Lancet. 2026 Jul 15:S0140-6736(26)00665-3. doi: 10.1016/S0140-6736(26)00665.
    >> Share

  10. CRIVELLI L, Suemoto CK, Sosa AL, Lopera F, et al
    Multidomain lifestyle intervention for the prevention of cognitive decline in at-risk older adults in Latin America (LatAm-FINGERS): a single-blind, multicentre, randomised controlled trial.
    Lancet. 2026 Jul 13:S0140-6736(26)01278-X. doi: 10.1016/S0140-6736(26)01278.
    >> Share

    June 2026
  11. DIPPEL DWJ, Cornelissen SA
    Tirofiban and thrombectomy for acute ischaemic stroke.
    Lancet. 2026 Jun 24:S0140-6736(26)01232-8. doi: 10.1016/S0140-6736(26)01232.
    >> Share

  12. HUANG H, Xu S, Qin T, Wang M, et al
    Efficacy and safety of tirofiban after successful endovascular reperfusion in acute ischaemic stroke (ATTRACTION) in China: a multicentre, double-blind, randomised controlled trial.
    Lancet. 2026 Jun 24:S0140-6736(26)00983-9. doi: 10.1016/S0140-6736(26)00983.
    >> Share

  13. LU Y, Wang Y
    Minocycline for acute ischaemic stroke: limitations of the EMPHASIS trial - Authors' reply.
    Lancet. 2026;407:2290.
    >> Share

  14. GHOZY S, Abbas AS, Kadirvel R, Rabinstein AA, et al
    Minocycline for acute ischaemic stroke: limitations of the EMPHASIS trial.
    Lancet. 2026;407:2289-2290.
    >> Share

    May 2026
  15. NIKOLCHEVA T, Pagano G, Anzures-Cabrera J, Trundell D, et al
    Efficacy and safety of intravenous prasinezumab in individuals with early-stage Parkinson's disease on stable symptomatic monotherapy (PADOVA): a phase 2b, multicentre, randomised, double-blind, placebo-controlled study.
    Lancet. 2026;407:2227-2240.
    >> Share


  16. Updated trends in the global prevalence and burden of mental disorders, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.
    Lancet. 2026;407:2040-2064.
    >> Share

  17. LEE JM, Lee SH, Gim DH, Lee SY, et al
    Coronary microvascular dysfunction and cardiovascular outcomes (Multicenter FLOW-CMD Registry): a prospective, multicentre cohort study in South Korea.
    Lancet. 2026 May 21:S0140-6736(26)00666-5. doi: 10.1016/S0140-6736(26)00666.
    >> Share

  18. WANG A, Xia X, Tang Y, Zhang F, et al
    Ticagrelor with aspirin dual antiplatelet therapy combined with intravenous thrombolysis in patients with ischaemic stroke in China (TAPIS): a multicentre, double-blind, randomised controlled trial.
    Lancet. 2026;407:1919-1928.
    >> Share

  19. ZWAM WV, Fischer U
    Is ATLAS lifting the burden of stroke in people with large-vessel occlusion and low ASPECTS scores?
    Lancet. 2026 May 7:S0140-6736(26)00873-1. doi: 10.1016/S0140-6736(26)00873.
    >> Share

  20. SARRAJ A, Thomalla G, Yoshimura S, Huo X, et al
    Endovascular thrombectomy for patients with large-core ischaemic stroke presenting up to 24 h after onset (ATLAS): a systematic review and individual patient data meta-analysis with central imaging adjudication.
    Lancet. 2026 May 7:S0140-6736(26)00876-7. doi: 10.1016/S0140-6736(26)00876.
    >> Share

    April 2026
  21. ZENG G, Bidel Z, Yang Q, Canoy D, et al
    Pharmacological blood-pressure lowering for the prevention of cardiovascular disease and death across the full spectrum of chronic kidney disease severity: an individual-participant data meta-analysis.
    Lancet. 2026;407:1626-1638.
    >> Share

  22. DU X, Anderson CS
    Off-target benefits of influenza vaccination in cardiovascular disease - Authors' reply.
    Lancet. 2026;407:1600.
    >> Share

    March 2026
  23. DELEWI R, Aarts HM, Broeze GM, Hemelrijk KI, et al
    Deferral of percutaneous coronary intervention in patients undergoing transcatheter aortic valve implantation (PRO-TAVI): an investigator-initiated, multicentre, open-label, non-inferiority, randomised controlled trial.
    Lancet. 2026 Mar 29:S0140-6736(26)00308-9. doi: 10.1016/S0140-6736(26)00308.
    >> Share

  24. KANG J, Park S, Yang HM, Shin ES, et al
    Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention: 10-year follow-up of the HOST-EXAM trial.
    Lancet. 2026 Mar 29:S0140-6736(26)00422-8. doi: 10.1016/S0140-6736(26)00422.
    >> Share

  25. ZHU Y, Cheng Z, Zhao Y, Han L, et al
    Angiography-derived fractional flow reserve versus coronary angiography to guide coronary artery bypass grafting in patients undergoing surgical valve procedures with concomitant coronary artery disease in China (FAVOR IV-QVAS): a multicentre, triple-
    Lancet. 2026;407:1161-1170.
    >> Share

  26. COLOMBATTI R, Jastaniah W, Makani J, Andemariam B, et al
    Sickle cell disease.
    Lancet. 2026;407:1095-1111.
    >> Share

  27. LANE DA, Andrade JG, Arbelo E, Boriani G, et al
    Atrial fibrillation.
    Lancet. 2026;407:1000-1013.
    >> Share

    February 2026

  28. Assessment of adverse effects attributed to statin therapy in product labels: a meta-analysis of double-blind randomised controlled trials.
    Lancet. 2026;407:689-703.
    >> Share

  29. XIONG Y, Alemseged F, Cao Z, Schwamm LH, et al
    Tenecteplase versus standard medical treatment for basilar artery occlusion within 24 h (TRACE-5): a multicentre, prospective, randomised, open-label, blinded-endpoint, superiority, phase 3 trial.
    Lancet. 2026 Feb 5:S0140-6736(25)02633-9. doi: 10.1016/S0140-6736(25)02633.
    >> Share

  30. TSIVGOULIS G, Palaiodimou L, Turc G
    Intravenous tenecteplase for acute ischaemic stroke within 24 h due to basilar artery occlusion.
    Lancet. 2026 Feb 5:S0140-6736(26)00139-X. doi: 10.1016/S0140-6736(26)00139.
    >> Share

  31. ANDERSON CS, Chen C, Salman RA
    Testing early haemostatic therapy for acute intracerebral haemorrhage.
    Lancet. 2026 Feb 4:S0140-6736(26)00146-7. doi: 10.1016/S0140-6736(26)00146.
    >> Share

  32. BRODERICK JP, Naidech AM, Elm JJ, Toyoda K, et al
    Recombinant factor VIIa versus placebo for spontaneous intracerebral haemorrhage within 2 h of symptom onset (FASTEST): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
    Lancet. 2026 Feb 4:S0140-6736(26)00097-8. doi: 10.1016/S0140-6736(26)00097.
    >> Share

    January 2026
  33. WENZL FA, Ow KW, Velders MA, Tyrer F, et al
    Prediction of mortality, bleeding, and ischaemic events in patients with cancer and acute coronary syndrome: a model development and validation study.
    Lancet. 2026;407:515-528.
    >> Share

  34. LU Y, Guan L, Wu J, Yang Q, et al
    Efficacy and safety of minocycline in patients with acute ischaemic stroke (EMPHASIS): a multicentre, double-blind, randomised controlled trial.
    Lancet. 2026 Jan 30:S0140-6736(25)01862-8. doi: 10.1016/S0140-6736(25)01862.
    >> Share

  35. NAUCK MA, Tuttle KR, Tschop MH, Bluher M, et al
    Glucagon-like receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits.
    Lancet. 2026 Jan 14:S0140-6736(25)02105-1. doi: 10.1016/S0140-6736(25)02105.
    >> Share

  36. EKELUND U, Tarp J, Ding D, Sanchez-Lastra MA, et al
    Deaths potentially averted by small changes in physical activity and sedentary time: an individual participant data meta-analysis of prospective cohort studies.
    Lancet. 2026 Jan 13:S0140-6736(25)02219-6. doi: 10.1016/S0140-6736(25)02219.
    >> Share

    December 2025

  37. Global, regional, and national progress towards the 2030 global nutrition targets and forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2021.
    Lancet. 2025;404:2543-2583.
    >> Share

  38. KEDHI E, Hermanides RS, Dambrink JE, Singh SK, et al
    TransCatheter aortic valve implantation and fractional flow reserve-guided percutaneous coronary intervention versus conventional surgical aortic valve replacement and coronary bypass grafting for treatment of patients with aortic valve stenosis and c
    Lancet. 2025;404:2593-2602.
    >> Share

  39. ANDERSON CS, Sui Y, Urrutia VC
    The importance of patient selection in stroke monitoring research - Authors' reply.
    Lancet. 2025;406:2756.
    >> Share

  40. HAYASHI S, Yasuda T, Shiraishi A
    The importance of patient selection in stroke monitoring research.
    Lancet. 2025;406:2755-2756.
    >> Share

  41. MOAYAD L, Mihan A, Peters SAE, Van Spall HGC, et al
    Inclusion of women who are pregnant, lactating, or of reproductive potential in clinical trials: health, ethical, and regulatory considerations.
    Lancet. 2025;406:2858-2864.
    >> Share

    November 2025
  42. MAKKAR RR, Thourani VH, Vahl TP, Yadav PK, et al
    Transcatheter aortic valve implantation with the Trilogy valve for symptomatic native aortic regurgitation (ALIGN-AR): a pivotal, multicentre, single-arm, investigational device exemption study.
    Lancet. 2025 Nov 16:S0140-6736(25)02215-9. doi: 10.1016/S0140-6736(25)02215.
    >> Share

  43. LEE JM
    Complete revascularisation in patients with acute myocardial infarction.
    Lancet. 2025 Nov 9:S0140-6736(25)02243-3. doi: 10.1016/S0140-6736(25)02243.
    >> Share

  44. KANG J, Park KW, Han JK, Hwang D, et al
    Dual antiplatelet therapy after percutaneous coronary intervention according to bleeding risk (HOST-BR): an open-label, multicentre, randomised clinical trial.
    Lancet. 2025;406:2244-2256.
    >> Share


  45. Global, regional, and national burden of chronic kidney disease in adults, 1990-2023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023.
    Lancet. 2025 Nov 7:S0140-6736(25)01853-7. doi: 10.1016/S0140-6736(25)01853.
    >> Share

    October 2025
  46. FEIGIN VL, Martins SO, Hankey GJ
    Rethinking atherosclerotic disease prevention.
    Lancet. 2025;406:1947.
    >> Share

  47. DEANFIELD J, Lincoff AM, Kahn SE, Emerson SS, et al
    Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial.
    Lancet. 2025 Oct 22:S0140-6736(25)01375-3. doi: 10.1016/S0140-6736(25)01375.
    >> Share


  48. Global burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.
    Lancet. 2025 Oct 12:S0140-6736(25)01917-8. doi: 10.1016/S0140-6736(25)01917.
    >> Share


  49. Global age-sex-specific all-cause mortality and life expectancy estimates for 204 countries and territories and 660 subnational locations, 1950-2023: a demographic analysis for the Global Burden of Disease Study 2023.
    Lancet. 2025 Oct 12:S0140-6736(25)01330-3. doi: 10.1016/S0140-6736(25)01330.
    >> Share


  50. Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Stud
    Lancet. 2025 Oct 12:S0140-6736(25)01637-X. doi: 10.1016/S0140-6736(25)01637.
    >> Share

    September 2025
  51. FRISONI GB, Aho E, Brayne C, Ciccarelli O, et al
    Alzheimer's disease outlook: controversies and future directions.
    Lancet. 2025;406:1424-1442.
    >> Share

  52. FOX NC, Belder C, Ballard C, Kales HC, et al
    Treatment for Alzheimer's disease.
    Lancet. 2025;406:1408-1423.
    >> Share

  53. FRISONI GB, Hansson O, Nichols E, Garibotto V, et al
    New landscape of the diagnosis of Alzheimer's disease.
    Lancet. 2025;406:1389-1407.
    >> Share


  54. The global, regional, and national burden of cancer, 1990-2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023.
    Lancet. 2025 Sep 24:S0140-6736(25)01635-6. doi: 10.1016/S0140-6736(25)01635.
    >> Share

  55. OCHOA-URREA M, Luo X, Vilella L, Lacuey N, et al
    Risk markers for sudden unexpected death in epilepsy: an observational, prospective, multicentre cohort study.
    Lancet. 2025 Sep 17:S0140-6736(25)01636-8. doi: 10.1016/S0140-6736(25)01636.
    >> Share

    August 2025
  56. ROSSELLO X, Prescott EIB, Kristensen AMD, Latini R, et al
    beta blockers after myocardial infarction with mildly reduced ejection fraction: an individual patient data meta-analysis of randomised controlled trials.
    Lancet. 2025 Aug 29:S0140-6736(25)01592-2. doi: 10.1016/S0140-6736(25)01592.
    >> Share

  57. GUO X, Sun G, Xu Y, Zhou S, et al
    Benefit-harm trade-offs of intensive blood pressure control versus standard blood pressure control on cardiovascular and renal outcomes: an individual participant data analysis of randomised controlled trials.
    Lancet. 2025 Aug 28:S0140-6736(25)01391-1. doi: 10.1016/S0140-6736(25)01391.
    >> Share

  58. VALGIMIGLI M, Choi KH, Giacoppo D, Gragnano F, et al
    Clopidogrel versus aspirin for secondary prevention of coronary artery disease: a systematic review and individual patient data meta-analysis.
    Lancet. 2025 Aug 28:S0140-6736(25)01562-4. doi: 10.1016/S0140-6736(25)01562.
    >> Share

  59. KIM MC, Ahn JH, Hyun DY, Lim Y, et al
    Immediate versus staged complete revascularisation during index admission in patients with ST-segment elevation myocardial infarction and multivessel disease (OPTION-STEMI): a multicentre, non-inferiority, open-label, randomised trial.
    Lancet. 2025 Aug 28:S0140-6736(25)01529-6. doi: 10.1016/S0140-6736(25)01529.
    >> Share

  60. ANDERSON CS, Hua C, Wang Z, Wang C, et al
    Influenza vaccination to improve outcomes for patients with acute heart failure (PANDA II): a multiregional, seasonal, hospital-based, cluster-randomised, controlled trial in China.
    Lancet. 2025 Aug 28:S0140-6736(25)01485-0. doi: 10.1016/S0140-6736(25)01485.
    >> Share

  61. ROSSIGNOL P, Zannad F, Massy Z, Azizi M, et al
    Spironolactone in patients on chronic haemodialysis at high risk of adverse cardiovascular outcomes (ALCHEMIST): a multicentre, double-blind, randomised, placebo-controlled trial and updated meta-analysis.
    Lancet. 2025;406:705-718.
    >> Share

  62. ROSENTHAL LS, Farag M, Aziz NA, Bang J, et al
    Vesicular monoamine transport inhibitors: current uses and future directions.
    Lancet. 2025;406:650-664.
    >> Share

  63. CHENG SP, Chen PH, Jhou HJ
    Timing of cardiac surgery and anticoagulants after acute ischaemic stroke.
    Lancet. 2025;406:601.
    >> Share

  64. WERRING DJ, Dehbi HM, Best JG, Nash PS, et al
    Timing of cardiac surgery and anticoagulants after acute ischaemic stroke - Authors' reply.
    Lancet. 2025;406:601-602.
    >> Share

  65. POCAR M, Barbero C, Cerrato P, De Rosa FG, et al
    Timing of cardiac surgery and anticoagulants after acute ischaemic stroke.
    Lancet. 2025;406:600-601.
    >> Share

    June 2025

  66. Global, regional, and national trends in routine childhood vaccination coverage from 1980 to 2023 with forecasts to 2030: a systematic analysis for the Global Burden of Disease Study 2023.
    Lancet. 2025 Jun 24:S0140-6736(25)01037-2. doi: 10.1016/S0140-6736(25)01037.
    >> Share

  67. ZIAI WC, Tsivgoulis G
    Timing of anticoagulation after ischaemic stroke and atrial fibrillation: better swift than sorry.
    Lancet. 2025 Jun 23:S0140-6736(25)00676-2. doi: 10.1016/S0140-6736(25)00676.
    >> Share

  68. DEHBI HM, Fischer U, Asberg S, Milling TJ, et al
    Collaboration on the optimal timing of anticoagulation after ischaemic stroke and atrial fibrillation: a systematic review and prospective individual participant data meta-analysis of randomised controlled trials (CATALYST).
    Lancet. 2025 Jun 23:S0140-6736(25)00439-8. doi: 10.1016/S0140-6736(25)00439.
    >> Share

  69. DENT E, Clegg A, Roller-Wirnsberger R, Vetrano DL, et al
    Reorienting frailty in clinical practice, public health, and policy: the Lancet Commission on Frailty.
    Lancet. 2025 Jun 5:S0140-6736(25)01101-8. doi: 10.1016/S0140-6736(25)01101.
    >> Share

    May 2025
  70. ASHCRAFT S
    Safety of low-intensity monitoring after thrombolysis in acute ischaemic stroke.
    Lancet. 2025;405:1884-1885.
    >> Share

  71. SHNEIDER NA, Harms MB, Korobeynikov VA, Rifai OM, et al
    Antisense oligonucleotide jacifusen for FUS-ALS: an investigator-initiated, multicentre, open-label case series.
    Lancet. 2025 May 22:S0140-6736(25)00513-6. doi: 10.1016/S0140-6736(25)00513.
    >> Share

  72. ANDERSON CS, Summers D, Ouyang M, Sui Y, et al
    Safety and efficacy of low-intensity versus standard monitoring following intravenous thrombolytic treatment in patients with acute ischaemic stroke (OPTIMISTmain): an international, pragmatic, stepped-wedge, cluster-randomised, controlled non-inferio
    Lancet. 2025 May 20:S0140-6736(25)00549-5. doi: 10.1016/S0140-6736(25)00549.
    >> Share

  73. MAKKAR RR, Ramana RK, Gnall E, Ramlawi B, et al
    ACURATE neo2 valve versus commercially available transcatheter heart valves in patients with severe aortic stenosis (ACURATE IDE): a multicentre, randomised, controlled, non-inferiority trial.
    Lancet. 2025 May 20:S0140-6736(25)00319-8. doi: 10.1016/S0140-6736(25)00319.
    >> Share

  74. SONG L, Li Q, Anderson CS
    Traditional Chinese medicine for acute intracerebral haemorrhage - Authors' reply.
    Lancet. 2025;405:1741-1742.
    >> Share

    March 2025
  75. CHOI KH, Park YH, Lee JY, Jeong JO, et al
    Efficacy and safety of clopidogrel versus aspirin monotherapy in patients at high risk of subsequent cardiovascular event after percutaneous coronary intervention (SMART-CHOICE 3): a randomised, open-label, multicentre trial.
    Lancet. 2025 Mar 28:S0140-6736(25)00449-0. doi: 10.1016/S0140-6736(25)00449.
    >> Share

  76. FEARON WF, Zimmermann FM, Ding VY, Takahashi K, et al
    Outcomes after fractional flow reserve-guided percutaneous coronary intervention versus coronary artery bypass grafting (FAME 3): 5-year follow-up of a multicentre, open-label, randomised trial.
    Lancet. 2025 Mar 28:S0140-6736(25)00505-7. doi: 10.1016/S0140-6736(25)00505.
    >> Share


  77. Global, regional, and national burden of household air pollution, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.
    Lancet. 2025 Mar 18:S0140-6736(24)02840-X. doi: 10.1016/S0140-6736(24)02840.
    >> Share

    February 2025

  78. Global, regional, and national prevalence of adult overweight and obesity, 1990-2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021.
    Lancet. 2025 Feb 28:S0140-6736(25)00355-1. doi: 10.1016/S0140-6736(25)00355.
    >> Share


  79. Global, regional, and national prevalence of child and adolescent overweight and obesity, 1990-2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021.
    Lancet. 2025 Feb 28:S0140-6736(25)00397-6. doi: 10.1016/S0140-6736(25)00397.
    >> Share

  80. SALMAN RA, Shoamanesh A
    Towards definitive evidence about anticoagulation for atrial fibrillation after intracranial haemorrhage.
    Lancet. 2025 Feb 26:S0140-6736(25)00366-6. doi: 10.1016/S0140-6736(25)00366.
    >> Share

  81. VELTKAMP R, Korompoki E, Harvey KH, Harvey ER, et al
    Direct oral anticoagulants versus no anticoagulation for the prevention of stroke in survivors of intracerebral haemorrhage with atrial fibrillation (PRESTIGE-AF): a multicentre, open-label, randomised, phase 3 trial.
    Lancet. 2025 Feb 26:S0140-6736(25)00333-2. doi: 10.1016/S0140-6736(25)00333.
    >> Share

  82. CHRISTENSON J, Hill MD, Swartz RH, Adams C, et al
    Efficacy and safety of intravenous nerinetide initiated by paramedics in the field for acute cerebral ischaemia within 3 h of symptom onset (FRONTIER): a phase 2, multicentre, randomised, double-blind, placebo-controlled study.
    Lancet. 2025;405:571-582.
    >> Share

  83. HILL MD, Goyal M, Demchuk AM, Menon BK, et al
    Efficacy and safety of nerinetide in acute ischaemic stroke in patients undergoing endovascular thrombectomy without previous thrombolysis (ESCAPE-NEXT): a multicentre, double-blind, randomised controlled trial.
    Lancet. 2025;405:560-570.
    >> Share

  84. KOOHI N, Simonyan S, Joffily L, Simister R, et al
    Testing hearing in suspected stroke: a diagnostic opportunity.
    Lancet. 2025;405:540-541.
    >> Share

  85. LIBERMAN AL, Levine SR
    Ischaemic brain neuroprotection: a true therapeutic frontier?
    Lancet. 2025;405:519-521.
    >> Share

  86. LI W, Lan J, Wei M, Liu L, et al
    Normobaric hyperoxia combined with endovascular treatment for acute ischaemic stroke in China (OPENS-2 trial): a multicentre, randomised, single-blind, sham-controlled trial.
    Lancet. 2025;405:486-497.
    >> Share

  87. DIPPEL DWJ, Janssen PM
    Effect of normobaric hyperoxia in ischaemic stroke.
    Lancet. 2025;405:442-443.
    >> Share

    January 2025
  88. WILLIAMS MC, Wereski R, Tuck C, Adamson PD, et al
    Coronary CT angiography-guided management of patients with stable chest pain: 10-year outcomes from the SCOT-HEART randomised controlled trial in Scotland.
    Lancet. 2025;405:329-337.
    >> Share

    December 2024
  89. NOGUEIRA RG, Jovin TG, Liu X, Hu W, et al
    Endovascular therapy for acute vertebrobasilar occlusion (VERITAS): a systematic review and individual patient data meta-analysis.
    Lancet. 2024 Dec 11:S0140-6736(24)01820-8. doi: 10.1016/S0140-6736(24)01820.
    >> Share

  90. HO JK, Hankey GJ
    Endovascular therapy for ischaemic stroke due to vertebrobasilar artery occlusion.
    Lancet. 2024 Dec 11:S0140-6736(24)02137-8. doi: 10.1016/S0140-6736(24)02137.
    >> Share


  91. Burden of disease scenarios by state in the USA, 2022-50: a forecasting analysis for the Global Burden of Disease Study 2021.
    Lancet. 2024;404:2341-2370.
    >> Share


  92. The burden of diseases, injuries, and risk factors by state in the USA, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.
    Lancet. 2024;404:2314-2340.
    >> Share

    November 2024
  93. DHILLON PS, Nguyen TN
    Temporary blood flow arrest during endovascular thrombectomy for acute ischaemic stroke.
    Lancet. 2024 Nov 20:S0140-6736(24)02461-9. doi: 10.1016/S0140-6736(24)02461.
    >> Share

  94. LIU J, Zhou Y, Zhang L, Li Z, et al
    Balloon guide catheters for endovascular thrombectomy in patients with acute ischaemic stroke due to large-vessel occlusion in China (PROTECT-MT): a multicentre, open-label, blinded-endpoint, randomised controlled trial.
    Lancet. 2024 Nov 20:S0140-6736(24)02315-8. doi: 10.1016/S0140-6736(24)02315.
    >> Share


  95. National-level and state-level prevalence of overweight and obesity among children, adolescents, and adults in the USA, 1990-2021, and forecasts up to 2050.
    Lancet. 2024 Nov 12:S0140-6736(24)01548-4. doi: 10.1016/S0140-6736(24)01548.
    >> Share

  96. WU S
    Integrative medicine for the treatment of stroke.
    Lancet. 2024 Nov 12:S0140-6736(24)02257-8. doi: 10.1016/S0140-6736(24)02257.
    >> Share

  97. GUO J, Chen X, Wu M, Wang D, et al
    Traditional Chinese medicine FYTF-919 (Zhongfeng Xingnao oral prescription) for the treatment of acute intracerebral haemorrhage: a multicentre, randomised, placebo-controlled, double-blind, clinical trial.
    Lancet. 2024 Nov 12:S0140-6736(24)02261-X. doi: 10.1016/S0140-6736(24)02261.
    >> Share


  98. Global, regional, and national stillbirths at 20 weeks' gestation or longer in 204 countries and territories, 1990-2021: findings from the Global Burden of Disease Study 2021.
    Lancet. 2024 Nov 4:S0140-6736(24)01925-1. doi: 10.1016/S0140-6736(24)01925.
    >> Share

  99. THOMALLA G, Bonekamp S, Fiehler J, Bendszus M, et al
    Endovascular thrombectomy for acute ischaemic stroke: the TENSION trial - Authors' reply.
    Lancet. 2024;404:1729-1730.
    >> Share

  100. JHOU HJ, Yang LY, Chen PH
    Endovascular thrombectomy for acute ischaemic stroke: the TENSION trial.
    Lancet. 2024;404:1728.
    >> Share

  101. WANG Z, Huang K, Huang ZX
    Endovascular thrombectomy for acute ischaemic stroke: the TENSION trial.
    Lancet. 2024;404:1728-1729.
    >> Share

  102. BROOCKS G, Kemmling A
    Endovascular thrombectomy for acute ischaemic stroke: the TENSION trial.
    Lancet. 2024;404:1727-1728.
    >> Share

    October 2024
  103. WERRING DJ, Dehbi HM, Ahmed N, Arram L, et al
    Optimal timing of anticoagulation after acute ischaemic stroke with atrial fibrillation (OPTIMAS): a multicentre, blinded-endpoint, phase 4, randomised controlled trial.
    Lancet. 2024 Oct 23:S0140-6736(24)02197-4. doi: 10.1016/S0140-6736(24)02197.
    >> Share

  104. SANDSET EC, de Sousa DA
    Optimal anticoagulation timing after ischaemic stroke in patients with atrial fibrillation.
    Lancet. 2024 Oct 23:S0140-6736(24)02259-1. doi: 10.1016/S0140-6736(24)02259.
    >> Share

    September 2024
  105. NGUYEN TN, Abdalkader M, Fischer U, Qiu Z, et al
    Endovascular management of acute stroke.
    Lancet. 2024;404:1265-1278.
    >> Share

  106. NARAGHI K, Marzo-Ortega H
    Progressive cervical osteophytosis and dysphagia associated with isotretinoin treatment for rosacea.
    Lancet. 2024;404:e4.
    >> Share


  107. Global burden of bacterial antimicrobial resistance 1990-2021: a systematic analysis with forecasts to 2050.
    Lancet. 2024 Sep 13:S0140-6736(24)01867-1. doi: 10.1016/S0140-6736(24)01867.
    >> Share

    August 2024
  108. HONG SJ, Lee SJ, Lee SH, Lee JY, et al
    Optical coherence tomography-guided versus angiography-guided percutaneous coronary intervention for patients with complex lesions (OCCUPI): an investigator-initiated, multicentre, randomised, open-label, superiority trial in South Korea.
    Lancet. 2024 Aug 30:S0140-6736(24)01454-5. doi: 10.1016/S0140-6736(24)01454.
    >> Share

  109. VALGIMIGLI M, Hong SJ, Gragnano F, Chalkou K, et al
    De-escalation to ticagrelor monotherapy versus 12 months of dual antiplatelet therapy in patients with and without acute coronary syndromes: a systematic review and individual patient-level meta-analysis of randomised trials.
    Lancet. 2024 Aug 30:S0140-6736(24)01616-7. doi: 10.1016/S0140-6736(24)01616.
    >> Share

  110. JHUND PS, Talebi A, Henderson AD, Claggett BL, et al
    Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis.
    Lancet. 2024 Aug 30:S0140-6736(24)01733-1. doi: 10.1016/S0140-6736(24)01733.
    >> Share

  111. KOSIBOROD MN, Deanfield J, Pratley R, Borlaug BA, et al
    Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials.
    Lancet. 2024 Aug 29:S0140-6736(24)01643-X. doi: 10.1016/S0140-6736(24)01643.
    >> Share

  112. DEANFIELD J, Verma S, Scirica BM, Kahn SE, et al
    Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial.
    Lancet. 2024;404:773-786.
    >> Share

  113. JAVED S, Zaidi DA, Yaqoob E
    Addressing the deficiencies in stroke care in Pakistan.
    Lancet. 2024;404:651-652.
    >> Share

  114. COUTTS SB, Sprigg N
    Human rights considerations are key when choosing a conference location.
    Lancet. 2024 Aug 16:S0140-6736(24)01503-4. doi: 10.1016/S0140-6736(24)01503.
    >> Share

  115. MANLEY GT, Maas AI
    The Glasgow Coma Scale at 50: looking back and forward.
    Lancet. 2024 Aug 14:S0140-6736(24)01596-4. doi: 10.1016/S0140-6736(24)01596.
    >> Share

    July 2024
  116. JOUNDI RA, Hu B, Rangarajan S, Leong DP, et al
    Activity limitations, use of assistive devices, and mortality and clinical events in 25 high-income, middle-income, and low-income countries: an analysis of the PURE study.
    Lancet. 2024 Jul 25:S0140-6736(24)01050-X. doi: 10.1016/S0140-6736(24)01050.
    >> Share

    June 2024
  117. LIU J, Li Y, Ge J, Yan X, et al
    Lowering systolic blood pressure to less than 120 mm Hg versus less than 140 mm Hg in patients with high cardiovascular risk with and without diabetes or previous stroke: an open-label, blinded-outcome, randomised trial.
    Lancet. 2024 Jun 27:S0140-6736(24)01028-6. doi: 10.1016/S0140-6736(24)01028.
    >> Share

  118. KELLY P, Lemmens R, Weimar C, Walsh C, et al
    Long-term colchicine for the prevention of vascular recurrent events in non-cardioembolic stroke (CONVINCE): a randomised controlled trial.
    Lancet. 2024 Jun 7:S0140-6736(24)00968-1. doi: 10.1016/S0140-6736(24)00968.
    >> Share

  119. KATSANOS AH, Shoamanesh A
    Colchicine for the prevention of vascular events after non-cardioembolic stroke.
    Lancet. 2024 Jun 7:S0140-6736(24)01096-1. doi: 10.1016/S0140-6736(24)01096.
    >> Share

    May 2024
  120. BAUMBACH A, van Royen N, Amat-Santos IJ, Hudec M, et al
    LANDMARK comparison of early outcomes of newer-generation Myval transcatheter heart valve series with contemporary valves (Sapien and Evolut) in real-world individuals with severe symptomatic native aortic stenosis: a randomised non-inferiority trial.
    Lancet. 2024 May 22:S0140-6736(24)00821-3. doi: 10.1016/S0140-6736(24)00821.
    >> Share


  121. Burden of disease scenarios for 204 countries and territories, 2022-2050: a forecasting analysis for the Global Burden of Disease Study 2021.
    Lancet. 2024;403:2204-2256.
    >> Share


  122. Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.
    Lancet. 2024;403:2162-2203.
    >> Share

  123. ADLER AI, Coleman RL, Leal J, Whiteley WN, et al
    Post-trial monitoring of a randomised controlled trial of intensive glycaemic control in type 2 diabetes extended from 10 years to 24 years (UKPDS 91).
    Lancet. 2024 May 17:S0140-6736(24)00537-3. doi: 10.1016/S0140-6736(24)00537.
    >> Share

  124. COUTTS SB, Ankolekar S, Appireddy R, Arenillas JF, et al
    Tenecteplase versus standard of care for minor ischaemic stroke with proven occlusion (TEMPO-2): a randomised, open label, phase 3 superiority trial.
    Lancet. 2024 May 16:S0140-6736(24)00921-8. doi: 10.1016/S0140-6736(24)00921.
    >> Share

  125. SACCO S, Turc G
    Advances and challenges in the acute treatment of minor ischaemic stroke.
    Lancet. 2024 May 16:S0140-6736(24)00981-4. doi: 10.1016/S0140-6736(24)00981.
    >> Share

  126. HILKENS NA, Casolla B, Leung TW, de Leeuw FE, et al
    Stroke.
    Lancet. 2024 May 14:S0140-6736(24)00642-1. doi: 10.1016/S0140-6736(24)00642.
    >> Share

  127. BECK J, Fung C, Strbian D, Butikofer L, et al
    Decompressive craniectomy plus best medical treatment versus best medical treatment alone for spontaneous severe deep supratentorial intracerebral haemorrhage: a randomised controlled clinical trial.
    Lancet. 2024 May 14:S0140-6736(24)00702-5. doi: 10.1016/S0140-6736(24)00702.
    >> Share

  128. KLIJN CJ, Dammers R, Sprigg N
    Decompressive craniectomy for deep intracerebral haemorrhage: a SWITCH towards better outcomes?
    Lancet. 2024 May 14:S0140-6736(24)00703-7. doi: 10.1016/S0140-6736(24)00703.
    >> Share

    April 2024

  129. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: a sys
    Lancet. 2024 Apr 15:S0140-6736(24)00757-8. doi: 10.1016/S0140-6736(24)00757.
    >> Share

  130. GE Z, Kan J, Gao X, Raza A, et al
    Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT): a randomised, placebo-controlled, double-blind clinical trial.
    Lancet. 2024 Apr 5:S0140-6736(24)00473-2. doi: 10.1016/S0140-6736(24)00473.
    >> Share

  131. PARK SJ, Ahn JM, Kang DY, Yun SC, et al
    Preventive percutaneous coronary intervention versus optimal medical therapy alone for the treatment of vulnerable atherosclerotic coronary plaques (PREVENT): a multicentre, open-label, randomised controlled trial.
    Lancet. 2024 Apr 4:S0140-6736(24)00413-6. doi: 10.1016/S0140-6736(24)00413.
    >> Share


  132. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.
    Lancet. 2024 Apr 3:S0140-6736(24)00367-2. doi: 10.1016/S0140-6736(24)00367.
    >> Share

    March 2024
  133. VAHL TP, Thourani VH, Makkar RR, Hamid N, et al
    Transcatheter aortic valve implantation in patients with high-risk symptomatic native aortic regurgitation (ALIGN-AR): a prospective, multicentre, single-arm study.
    Lancet. 2024 Mar 26:S0140-6736(23)02806-4. doi: 10.1016/S0140-6736(23)02806.
    >> Share

  134. MELLO A, Stehr D, Bujarski K, Duchaine B, et al
    Visualising facial distortions in prosopometamorphopsia.
    Lancet. 2024;403:1176.
    >> Share


  135. Global fertility in 204 countries and territories, 1950-2021, with forecasts to 2100: a comprehensive demographic analysis for the Global Burden of Disease Study 2021.
    Lancet. 2024 Mar 19:S0140-6736(24)00550-6. doi: 10.1016/S0140-6736(24)00550.
    >> Share

  136. CHEN WG, Edwards E, Iyengar S, Finkelstein R, et al
    Music and medicine: quickening the tempo of progress.
    Lancet. 2024 Mar 18:S0140-6736(24)00477-X. doi: 10.1016/S0140-6736(24)00477.
    >> Share


  137. Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950-2021, and the impact of the COVID-19 pandemic: a comprehensive demographic analysis for the Global Burden
    Lancet. 2024 Mar 8:S0140-6736(24)00476-8. doi: 10.1016/S0140-6736(24)00476.
    >> Share

    February 2024
  138. CONSOLI A, Gory B
    Long-term results of mechanical thrombectomy for large ischaemic stroke.
    Lancet. 2024 Feb 8:S0140-6736(24)00158-2. doi: 10.1016/S0140-6736(24)00158.
    >> Share

  139. SARRAJ A, Abraham MG, Hassan AE, Blackburn S, et al
    Endovascular thrombectomy plus medical care versus medical care alone for large ischaemic stroke: 1-year outcomes of the SELECT2 trial.
    Lancet. 2024 Feb 8:S0140-6736(24)00050-3. doi: 10.1016/S0140-6736(24)00050.
    >> Share

    January 2024
  140. BEN-SHLOMO Y, Darweesh S, Llibre-Guerra J, Marras C, et al
    The epidemiology of Parkinson's disease.
    Lancet. 2024;403:283-292.
    >> Share

    November 2023
  141. FROST R, Avgerinou C, Kalwarowsky S, Mahmood F, et al
    Enabling health and maintaining independence for older people at home (HomeHealth trial): a multicentre randomised controlled trial.
    Lancet. 2023;402 Suppl 1:S42.
    >> Share

  142. BARRADO-MARTIN Y, Frost R, Catchpole J, Rookes T, et al
    Goal setting as part of a holistic intervention to promote independence in older people with mild frailty: a process evaluation alongside a randomised controlled trial.
    Lancet. 2023;402 Suppl 1:S1.
    >> Share

  143. LIU L, Li X, Marshall IJ, Bhalla A, et al
    Trajectories of depressive symptoms 10 years after stroke and associated risk factors: a prospective cohort study.
    Lancet. 2023;402 Suppl 1:S64.
    >> Share

    October 2023
  144. MESSERLI FH, Bangalore S, Mandrola JM
    beta blockers switched to first-line therapy in hypertension.
    Lancet. 2023 Oct 13:S0140-6736(23)01733-6. doi: 10.1016/S0140-6736(23)01733.
    >> Share

  145. DIPPEL DWJ, Roozenbeek B
    Thrombectomy for acute ischaemic stroke without advanced imaging.
    Lancet. 2023 Oct 10:S0140-6736(23)02229-8. doi: 10.1016/S0140-6736(23)02229.
    >> Share

  146. BENDSZUS M, Fiehler J, Subtil F, Bonekamp S, et al
    Endovascular thrombectomy for acute ischaemic stroke with established large infarct: multicentre, open-label, randomised trial.
    Lancet. 2023 Oct 10:S0140-6736(23)02032-9. doi: 10.1016/S0140-6736(23)02032.
    >> Share

    August 2023
  147. MAKKAR RR, Kapadia S, Chakravarty T, Cubeddu RJ, et al
    Outcomes of repeat transcatheter aortic valve replacement with balloon-expandable valves: a registry study.
    Lancet. 2023 Aug 31:S0140-6736(23)01636-7. doi: 10.1016/S0140-6736(23)01636.
    >> Share

  148. MAJOIE CB, Cavalcante F, Gralla J, Yang P, et al
    Value of intravenous thrombolysis in endovascular treatment for large-vessel anterior circulation stroke: individual participant data meta-analysis of six randomised trials.
    Lancet. 2023 Aug 25:S0140-6736(23)01142-X. doi: 10.1016/S0140-6736(23)01142.
    >> Share

  149. HANKEY GJ
    Does thrombolysis add value to thrombectomy for acute ischaemic stroke?
    Lancet. 2023 Aug 25:S0140-6736(23)01202-3. doi: 10.1016/S0140-6736(23)01202.
    >> Share

  150. WILKOFF BL, Filippatos G, Leclercq C, Gold MR, et al
    Adaptive versus conventional cardiac resynchronisation therapy in patients with heart failure (AdaptResponse): a global, prospective, randomised controlled trial.
    Lancet. 2023 Aug 24:S0140-6736(23)00912-1. doi: 10.1016/S0140-6736(23)00912.
    >> Share

    July 2023
  151. STRANDELL A, Hellgren M
    Time to stop routine prescription of low-molecular-weight heparin to women with recurrent pregnancy loss and inherited thrombophilia.
    Lancet. 2023;402:6-7.
    >> Share

    June 2023
  152. HUANG C, Huang L, Wang Y, Li X, et al
    6-month consequences of COVID-19 in patients discharged from hospital: a cohort study.
    Lancet. 2023 Jun 12:S0140-6736(23)00810-3. doi: 10.1016/S0140-6736(23)00810.
    >> Share

    May 2023
  153. MA L, Hu X, Song L, Chen X, et al
    The third Intensive Care Bundle with Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial (INTERACT3): an international, stepped wedge cluster randomised controlled trial.
    Lancet. 2023 May 24:S0140-6736(23)00806-1. doi: 10.1016/S0140-6736(23)00806.
    >> Share

    April 2023
  154. WARDLAW JM
    Even more benefit with endovascular treatment for patients with acute ischaemic stroke: MR CLEAN-LATE.
    Lancet. 2023;401:1317-1319.
    >> Share

  155. HAWKEY C
    Helicobacter pylori eradication and aspirin: a puzzle yet to be solved - Author's reply.
    Lancet. 2023;401:1266.
    >> Share

  156. GATTA L, Zullo A, Vaira D
    Helicobacter pylori eradication and aspirin: a puzzle yet to be solved.
    Lancet. 2023;401:1265-1266.
    >> Share

  157. LI Y, Liang Z, Stone GW, Han Y, et al
    BRIGHT-4 trial: bivalirudin strikes back - Authors' reply.
    Lancet. 2023;401:1158.
    >> Share

  158. PIRIOU PG, Manigold T, Letocart V, Guerin P, et al
    BRIGHT-4 trial: bivalirudin strikes back.
    Lancet. 2023;401:1157-1158.
    >> Share

    March 2023
  159. OLTHUIS SGH, Pirson FAV, Pinckaers FME, Hinsenveld WH, et al
    Endovascular treatment versus no endovascular treatment after 6-24 h in patients with ischaemic stroke and collateral flow on CT angiography (MR CLEAN-LATE) in the Netherlands: a multicentre, open-label, blinded-endpoint, randomised, controlled, phase
    Lancet. 2023 Mar 29:S0140-6736(23)00575-5. doi: 10.1016/S0140-6736(23)00575.
    >> Share

  160. KLOK FA, Siegerink B
    Ordinal outcomes add value to clinical trials.
    Lancet. 2023;401:995.
    >> Share

  161. HE J, Ouyang N, Guo X, Sun G, et al
    Effectiveness of a non-physician community health-care provider-led intensive blood pressure intervention versus usual care on cardiovascular disease (CRHCP): an open-label, blinded-endpoint, cluster-randomised trial.
    Lancet. 2023 Mar 2:S0140-6736(22)02603-4. doi: 10.1016/S0140-6736(22)02603.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016